All Comparisons
Retatrutide vs Eloralintide
Research material comparison: purity standards, available formats, molecular data, batch COA documentation, and regulatory status. For in vitro research use only.
Retatrutide: BEloralintide: C
| Attribute | Retatrutide | Eloralintide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Weight Loss & Metabolic |
| Evidence Rating | B — Phase III / NDA Filed | C — Phase II Clinical Trials |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Phase II clinical trials by Eli Lilly. Active development as of 2025. |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon (increases energy expenditure, fat oxidation, thermogenesis). This triple synergy combines reduced cal... | Amylin receptor agonist that promotes satiety and reduces food intake through a pathway distinct from GLP-1 signaling. Amylin is normally co-secreted with insulin from pancreatic beta cells and acts on brain areas controlling appetite. |
| Half-Life | ~6 days (allows once-weekly dosing) | — |
| Bioavailability | SC injection | — |
| Molecular Weight | — | — |
| WADA Status | Not Prohibited | — |
| Research Half-Life | ~6 days (allows once-weekly dosing) | — |
| Key Use Cases |
|
|
| Safety Concerns |
|
|
| Contraindications |
|
|
| Regulatory (US) | Not FDA-approved. Phase 3 TRIUMPH program ongoing (Eli Lilly). TRIUMPH-4 reported 28.7% body weight loss at 12 mg over 68 weeks. Seven Phase 3 readouts expected in 2026. Regulatory submission expected 2026; approval anticipated 2027-2028. | Investigational New Drug (IND). Phase II trials ongoing. Not FDA-approved. |
Research Material Specifications
Catalog specifications for the corresponding research materials, including batch documentation coverage.
| Specification | Retatrutide | Eloralintide |
|---|---|---|
| Purity Standard | ≥98% | ≥98% |
| CAS Number | 2381089-83-2 | N/A |
| Molecular Formula | C₂₂₅H₃₄₈N₆₀O₆₈S₂ | N/A |
| Available Formats | 20mg, 10mg, 5mg, 30mg | 10mg |
| Batch COAs Published | — | — |
| Stock Status | In stock | Out of stock |
Availability at Volta Peptides
Research Disclaimer: This comparison is provided for educational purposes only. All products are sold exclusively for in vitro research use. The information presented is based on published preclinical and clinical research and does not constitute medical advice. Consult a qualified healthcare professional before making any decisions regarding peptide use.
Explore More
Comparisons
Compare any two peptides side-by-side or browse our curated popular matchups.